Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2022 Mar 21

PMID 35312767

Authors

Peter Ueda

Henrik Svanstrom

Anders Hviid

Bjorn Eliasson

Ann-Marie Svensson

Stefan Franzen

Soffia Gudbjornsdottir

Kristian Hveem

Christian Jonasson

Viktor Wintzell

Mads Melbye

Bjorn Pasternak

Affiliations

Soon will be listed here.

Citing Articles

Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.

Xu B, Zhou J Eur J Clin Pharmacol. 2024; 80(12):1959-1966.

PMID: 39285057 DOI: 10.1007/s00228-024-03759-6.

Type Disparity in Sodium-Glucose Cotransporter-2 Inhibitors in Incidences of Renal Cell Carcinoma: A Propensity-Score-Matched Cohort Study.

Lin T, Wang W, Yang T, Jong G Cancers (Basel). 2024; 16(11).

PMID: 38893264 PMC: 11171380. DOI: 10.3390/cancers16112145.

Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential.

Sun M, Sun J, Sun W, Li X, Wang Z, Sun L Front Pharmacol. 2024; 15:1369352.

PMID: 38595915 PMC: 11002155. DOI: 10.3389/fphar.2024.1369352.

Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.

Xu B, Kang B, Li S, Fan S, Zhou J J Endocrinol Invest. 2024; 47(10):2421-2436.

PMID: 38530620 DOI: 10.1007/s40618-024-02351-0.

Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure-Current Evidence in Special Populations.

Moady G, Ben Gal T, Atar S Life (Basel). 2023; 13(6).

PMID: 37374037 PMC: 10301138. DOI: 10.3390/life13061256.

References

Ueda P, Wintzell V, Melbye M, Eliasson B, Svensson A, Franzen S . Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia. 2021; 64(10):2204-2214. PMC: 8423638. DOI: 10.1007/s00125-021-05508-1. View

Dicembrini I, Nreu B, Mannucci E, Monami M . Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2019; 21(8):1871-1877. DOI: 10.1111/dom.13745. View

Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J . SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017; 60(10):1862-1872. DOI: 10.1007/s00125-017-4370-8. View

Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A, Franzen S . Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ. 2020; 369:m1186. PMC: 7188014. DOI: 10.1136/bmj.m1186. View

Garcia M, Arteche-Martinez U, Lertxundi U, Aguirre C . SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database. J Clin Pharmacol. 2020; 61(2):187-192. DOI: 10.1002/jcph.1722. View